Genetic disruption of the PI3K regulatory subunits, p85 , p55 , and p50 , normalizes mutant PTPN11-induced hypersensitivity to GM-CSF
Authors:
Open Access
- 7 February 2012
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 97 (7) , 1042-1047
Abstract
Juvenile myelomonocytic leukemia is a lethal disease of children characterized by hypersensitivity of hematopoietic progenitors to granulocyte macrophage-colony stimulating factor. Mutations in PTPN11, the gene encoding the protein tyrosine phosphatase Shp2, are common in juvenile myelomonocytic leukemia and induce hyperactivation of the phosphoinositide-3-kinase pathway. We found that genetic disruption of Pik3r1, the gene encoding the Class IA phosphoinositide-3-kinase regulatory subunits p85α, p55α and p50α, significantly reduced hyperproliferation and hyperphosphorylation of Akt in gain-of-function Shp2 E76K-expressing cells. Elevated protein levels of the phosphoinositide-3-kinase catalytic subunit, p110δ, in the Shp2 E76K-expressing Pik3r1−/− cells suggest that p110δ may be a crucial mediator of mutant Shp2-induced phosphoinositide-3-kinase hyperactivation. Consistently, treatment with the p110δ-specific inhibitor, IC87114, or the clinical grade pan-phosphoinositide-3-kinase inhibitor, GDC-0941, reduced granulocyte macrophage-colony stimulating factor hypersensitivity. Treatment with the farnesyltransferase inhibitor, tipifarnib, showed that Shp2 E76K induces hyperactivation of phosphoinositide-3-kinase by both Ras-dependent and Ras-independent mechanisms. Collectively, these findings implicate Class IA phosphoinositide-3-kinase as a relevant molecular target in juvenile myelomonocytic leukemia.Keywords
This publication has 30 references indexed in Scilit:
- Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and LeukemogenesisJournal of Signal Transduction, 2011
- PI3K/p110δ is a novel therapeutic target in multiple myelomaBlood, 2010
- Mutations in CBL occur frequently in juvenile myelomonocytic leukemiaBlood, 2009
- Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Molecular Cancer Therapeutics, 2009
- Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/− mast cellsBlood, 2008
- Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survivalExperimental Hematology, 2008
- Class I PI3K in oncogenic cellular transformationOncogene, 2008
- Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunitCancer Cell, 2002
- Regulation and function of protein kinase B and MAP kinase activation by the IL-5/GM-CSF/IL-3 receptorOncogene, 1999
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994